Cystic Fibrosis: Meveol effective against Burkholderia Dolosa

The new generation of antimicrobial confirmed its potential with the evidence of effectiveness on this resistant bacterium kindly provided by Harvard Children's Hospital for which no therapeutic solution is available to date Apr 07, 2011 – Alaxia, a Lyons biotech that is developing the candidate drug Meveol hired an independent certified laboratory to confirm in vitro efficacy recorded by its microbiologists. The effect of Meveol has been studied on several strains of Burkholderia dolosa. Meveol bactericidal efficacy - over 99.9% - is observed in a few hours. These results were obtained as part of a research partnership with Harvard Children's Hospital, Boston (USA), as Burkholderia dolosa affects their cystic fibrosis patients. This highly pathogen strain for CF patients is resis...
Source: Alaxia - Category: Respiratory Medicine Source Type: news